APTO - Aptose Biosciences Inc. Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Aptose Biosciences Inc (APTO) - corporate logo

The share price for Aptose Biosciences Inc. (APTO) visualized below on the GURU.Markets platform, with an EV/EBITDA of , is based on the development of innovative small molecules for kinase inhibition in tumors. However, a severe cash burn puts tuspetinib trials at risk and threatens shareholders with delisting and capital loss. The business foundation remains the ownership of inhibitor patents, which promises future licensing payments.

APTO Aptose Biosciences Inc: Company Value to EBITDA in the range 07/04/2022 - 11/12/2026

aptose.com - analytical breakdowns and key metrics (APTO)

- current price and projected stock value:
Stock Price Aptose Biosciences|APTO - Price Target Chart
- market capitalization statistics:
Market Value APTO|APTO - Total Company Value
- book value of equity indicators:
Net Assets per Single Share Aptose Biosciences|APTO - Total Stockholders' Equity|Market Value to Book Value Ratio aptose.com|APTO - Company Assets
- business debt structure and liquidity details:
Total Debt to Capital Aptose Biosciences Inc.|APTO - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Aptose Biosciences|APTO - Company Aggregate Debts|Debt to Book Capitalization Ratio APTO|APTO - Long-Term Liabilities|Company Current Liabilities Aptose Biosciences|Quick Liquidity aptose.com
- business earnings and investment ratios data:
APTO - Company Net Income|Expected Profit Aptose Biosciences Inc.|APTO - Business Payback Period|Forward P/E Multiple Aptose Biosciences|APTO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio APTO|APTO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Aptose Biosciences|APTO - Earnings per share for the last twelve months|Quarterly EPS earnings growth aptose.com|APTO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Aptose Biosciences Inc.
Fundamental company analysis:APTO (Aptose)
Product sample of aptose.com

Investors evaluate capital management efficiency by comparing the total enterprise value of a business with its operating profit before depreciation and interest. This multiple determines the real value of assets, stripped of tax effects and debt load. For Aptose Biosciences Inc. (APTO), raw material supply chain disruption risks directly impact operating cash flow, which is reflected in the fluctuations of the EV/EBITDA ratio.

Direct competitors

EV/EBITDA Multiple TGTX (TG Therapeutics Corp)|Arcellx Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNDX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kura Oncology (KURA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA ADC Therapeutics S.A. (ADCT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Foghorn Therapeutics, Inc.|Company Value to EBITDA Vor Bio Inc. VOR|EV/EBITDA Multiple NKTX|coeptistx.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATNM (Actinium Pharmaceuticals, Inc.)|EV/EBITDA Multiple Estrella Immunopharma Inc ESLA|CASI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio MRKR|INAB (IN8bio, Inc.) - Enterprise Value to EBITDA Ratio|ERNA: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GT Biopharma|Company Value to EBITDA Bio-Path Holdings Inc. BPTH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MEI Pharma Corp (MEIP)|Total Company Value to Operating Income Before Depreciation Ratio vincerx.com